Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Central Apnea in Heart Failure: Physiological Mechanisms to Inform Treatment
NCT07210606Phase 4Recruiting
- Sponsor
- VA Office of Research & Development
- Start
- Sep 2026
- Primary completion
- Jun 2030
- Modality
- Inhalation Devices, Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of trazodone hydrochloride prolonged-release tablets, oxygen in central sleep apnea (CSA), sponsored by VA Office of Research & Development. Started Sep 2026; status: recruiting.
02
Drugs
trazodone hydrochloride prolonged-release tabletsoxygen
03
Conditions
central sleep apnea (CSA)
Beyond the preview
Go deeper on NCT07210606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07210606.